AC
ENVB icon

Armistice Capital’s Enveric Biosciences ENVB Stock Holding History

Armistice Capital’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2K Buy
+32,000
New +$76.9K ﹤0.01% 319
2024
Q1 		– Sell
-1,517
Closed -$355K – 361
2023
Q4 		$355K Buy
+1,517
New +$466K ﹤0.01% 212

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Armistice Capital's ENVB Position: Q2 2026 in Review

Armistice Capital opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 32,000 shares worth $44.2K. The stake represents ﹤0.01% of the portfolio and ranks #319 among its holdings. This is a return to the name: Armistice Capital previously reported a position in ENVB as recently as Q4 2023.

Armistice Capital first reported a position in ENVB in Q4 2023 and has held it in 2 quarters since. The position peaked at $355K in Q4 2023. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • Armistice Capital held 32,000 shares of Enveric Biosciences worth $44.2K as of Q2 2026.
  • Enveric Biosciences was a new Armistice Capital position in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #319 holding.
  • Armistice Capital first reported a position in Enveric Biosciences in Q4 2023 and has held it in 2 quarters since.
  • Armistice Capital's Enveric Biosciences position peaked at $355K in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.